Loading clinical trials...

The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial | Clinical Trials | Clareo Health

UNKNOWNPHASE1

The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial

NCT01943136•Philippine Dermatological Society

View on ClinicalTrials.gov

Summary

This study will be an investigator-blinded, patient-blinded, assessor-blinded, parallel-group, randomized clinical trial. It aims to evaluate the efficacy of one-week twice-daily application of topical papaya leaf extract ointment compared to mupirocin ointment in achieving clinical cure among patients with impetigo.

Eligibility

Age

1 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy Filipino patients aged 1 year and above with primary impetigo, limited to less than or equal to 1% BSA, and involving only one body area

Exclusion Criteria

•Extensive impetigo (\>1% BSA), affecting more than one body area
•Systemic involvement (lymphadenopathy, fever, sepsis)
•Chronic comorbidities like diabetes mellitus, malignancy, chronic venous insufficiency
•Concurrent immunosuppressive therapy
•Patients ≤ 1 year
•Pregnant \& lactating patients

Locations (1)

St. Luke's Medical Center

Quezon City, NCR, Philippines

Key Dates

Start Date

August 1, 2013

Primary Completion Date

June 1, 2015

Last Updated

December 19, 2013

Enrollment

128

ESTIMATED participants

Conditions

Impetigo

Interventions

papaya 1% extract ointment

DRUG

mupirocin 2% ointment

DRUG

Contacts

Janine L. Quijano, MD

CONTACT

janinequijanoMD@gmail.com

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

NCT02090764

Impetigo

View study

COMPLETEDPHASE3

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

NCT00133848

Impetigo

View study

COMPLETEDPHASE4

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

NCT01126268

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial

Inclusion Criteria

Exclusion Criteria

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo

Citriodiol® and Impetigo